The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $81.73

Today's change+1.59 +1.98%
Updated February 10 4:00 PM EST. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $81.73

Today's change+1.59 +1.98%
Updated February 10 4:00 PM EST. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc up sharply

Vertex Pharmaceuticals Inc closed up sharply Wednesday, rallying (U.S.)$1.59 or 1.98% to (U.S.)$81.73. Over the last five days, shares have lost 12.94% and sit 2.88% above their 52-week low. This security has underperformed the S&P 500 by 14.15% during the last year.

Key company metrics

  • Open(U.S.) $82.26
  • Previous close(U.S.) $80.14
  • High(U.S.) $84.06
  • Low(U.S.) $80.25
  • Bid / Ask(U.S.) $81.10 / (U.S.) $83.66
  • YTD % change-35.05%
  • Volume4,115,279
  • Average volume (10-day)4,001,685
  • Average volume (1-month)3,012,003
  • Average volume (3-month)2,232,502
  • 52-week range(U.S.) $79.44 to (U.S.) $143.45
  • Beta0.73
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward36.04×
  • Forward PEG0.62×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.32
Updated February 10 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-57.15%

Although this company's net profit margin is negative, it is above the industry average and implies that Vertex Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.79%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue418310166139
Total other revenue--------
Total revenue418310166139
Gross profit355280151129
Total cost of revenue6330159
Total operating expense473380337310
Selling / general / administrative971009486
Research & development310246224216
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)222-3
Other operating expenses, total1213
Operating income-55-70-171-172
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-78-92-191-198
Income after tax-76-94-221-199
Income tax, total-11300
Net income-76-95-189-199
Total adjustments to net income--------
Net income before extra. items-76-95-189-199
Minority interest1-1320
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-76-95-189-199
Inc. avail. to common incl. extra. items-76-95-189-199
Diluted net income-76-95-189-199
Dilution adjustment--------
Diluted weighted average shares243242241239
Diluted EPS excluding extraordinary itemsvalue per share-0.31-0.39-0.78-0.83
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.31-0.39-0.78-0.84